Clinical trials: Patient With Schizophrenia Spectrum Disorder
Antipsychotic-induced Weight Gain (AIWG)
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with…
- Trial name
- GRATITUDE (NCT03818256)
- Testing
- Miricorilant
- Where
- 27 sites in United States
- Volunteers
- 71 people
- Sponsor
- Corcept Therapeutics
Schizophrenia
A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients
A direct comparison of Positron Emission Tomography (PET) (11C-Raclopride) and Single Photon Emission Computed Tomography (SPECT) (123I-IBZM) D2 RO measurements would allow GSK to gain understanding on the SPECT results obtained…
- Trial name
- NCT00392743
- Testing
- pet/spect scan
- Where
- 7 sites in Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia and Schizoaffective Disorder
Relationship Between Physical Fitness and Psychopathology, Cognition and Quality of Life in Patients Diagnosed With Schizophrenia: a Mixed Method Study.
The goal of this observational study is to assess the physical fitness and the influence of possible factors (disease symptomatology, cognitive status, patient functioning and degree of perceived quality of life) on patients…
- Trial name
- COFESQ (NCT06824584)
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Universidade da Coruña
Schizophrenia
Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia
The aim of the present study is to detect changes in the dopamine system in the brain of patients with schizophrenia, especially when pretreated with antipsychotic medication.
- Trial name
- NCT03911726
- Testing
- Single PET/MR-measurement
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia Spectrum and Other Psychotic Disorders
Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial
The aim of this study is to explore new safe effective psychotherapeutic interventions for schizophrenia through assessing the efficacy and acceptability of complementary "Insight Enhancement Program" (IEP) and "Metacognitive…
- Trial name
- NCT03955549
- Testing
- Insight Enhancement Program (IEP), Metacognitive Training for Psychosis (MCT), Treatment As Usual (TAU)
- Where
- Egypt
- Volunteers
- 99 people
- Sponsor
- Agiad Psychiatry Hospital
Schizophrenia, Schizoaffective Disorder
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
The primary features of schizophrenia and schizoaffective disorder are characterized by positive (inability to think clearly and distinguish reality from fantasy) and negative symptoms (reduction or absence of normal behavior or…
- Trial name
- NCT00212784
- Testing
- asenapine, olanzapine
- Volunteers
- 1,225 people
- Sponsor
- Organon and Co
Schizophrenia, Alzheimer's Disease
The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients
This study in patients with stable schizophrenia will investigate the effect of JNJ-39393406 on Event Related Potentials (Auditory Evoked Potential [AEP] P50, AEP P300 and Mismatch Negativity [MMN]) after single dose…
- Conditions
- Schizophrenia, Alzheimer's Disease, Cognition Disorders
- Trial name
- NCT01137799
- Testing
- JNJ-39393406
- Where
- 4 sites in Germany
- Volunteers
- 47 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia, Constipation
Kombucha Tea for Improving Defecation in Patients With Schizophrenia- a Randomized Controlled Study
Patients with schizophrenia frequently have difficulties in bowel habits due to medical adverse effects and unhealthy lifestyle, and the use of various interventions to ameliorate the problems have been noted in clinical setting.
- Conditions
- Schizophrenia, Constipation, Kombucha Tea
- Trial name
- NCT06502509
- Testing
- Commercial Kombucha tea (Brand name E-Ben Organic Kombucha Lemon), Lemon tea
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- TsaoTun Psychiatric Center, Department of Health, Taiwan
Schizophrenia
Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy (effectiveness of drug) and safety of the antipsychotic paliperidone ER compared to another antipsychotic, quetiapine, and to placebo in patients who are acutely ill with…
- Trial name
- NCT00334126
- Volunteers
- 399 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia
This is a study designed to evaluate the efficacy and safety of lurasidone in acutely psychotic patients with chronic schizophrenia and to confirm the non-inferiority of lurasidone relative to quetiapine XR.
- Trial name
- NCT03465787
- Testing
- Lurasidone HCL 160 mg, Quetiapine XR 600 mg
- Where
- South Korea
- Volunteers
- 210 people
- Sponsor
- Bukwang Pharmaceutical
Chronic Schizophrenia
Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of 24 weeks memantine add-on treatment to risperidone for the treatment of negative symptomatology and cognitive impairment in patients with chronic schizophrenia.
- Trial name
- NCT00148616
- Testing
- Memantine
- Where
- Germany
- Volunteers
- 13 people
- Sponsor
- M. Schaefer, MD
Schizophrenia
A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients
The purpose of this study is to evaluate the effects of nicotinic alpha-7 MEM 3454 on P50 sensory gating in patients with Schizophrenia. The hypothesis is that MEM 3454 will normalize the P50 ratio.
- Trial name
- P50 (NCT00725855)
- Testing
- MEM 3454
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memory Pharmaceuticals
Schizophrenia
Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia
The purpose of this study is to evaluate the safety and tolerability of Lu AF11167 in patients with schizophrenia following various repeated dosing regimens of Lu AF11167 (alone or as added treatment to risperidone).
- Trial name
- NCT02202213
- Testing
- Lu AF11167
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Trial of D-Cycloserine in Schizophrenia
To characterize further the effects of D-cycloserine augmentation of antipsychotic treatment on negative symptoms, performance on neurocognitive tasks, and on markers for glutamatergic, dopaminergic and serotonergic function in…
- Trial name
- NCT00000371
- Testing
- D-cycloserine
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorder
Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia
The investigators would like to know the association of gene polymorphisms and metabolic adversities in clozapine-treated patients with schizophrenia in Taiwan.
- Trial name
- NCT01324167
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taipei Medical University WanFang Hospital
Randomized Controlled Trial
Exploring the Effect of Rumination-Focused Cognitive Behaviour Therapy in Patients With Schizophrenia
This study will explore the effect of Rumination-Focused Cognitive Behaviour Therapy on depressive symptoms in patients with schizophrenia for three months.
- Trial name
- NCT04442893
- Testing
- Rumination-Focused Cognitive Behaviour Therapy, Health Education programme
- Where
- Taiwan
- Volunteers
- 85 people
- Sponsor
- National Yang Ming Chiao Tung University
Schizophrenia
Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone
In this study we intend to compare the effect of Sertindole to that of Risperidone on cognitive impairment in schizophrenia. Hypothesis: Sertindole will be as effective as Risperidone for treating cognitive impairment in…
- Trial name
- NCT00480844
- Testing
- Sertindole, Risperidone
- Where
- 3 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Sheba Medical Center
Schizophrenia and Schizophrenia Spectrum Psychosis
Investigation of Using Non-Wearable Devices to Assess Sleep- Disordered Breathing in Hospitalized Patients With Schizophrenia
This research project aims to evaluate the prevalence of comorbid OSA and its impact on disease progression among hospitalized schizophrenia patients using non-wearable devices.
- Trial name
- IUNWD (NCT07192042)
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Schizophrenia and Related Disorders, Mitochondrial Alteration
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
The goal of this double-blind, placebo-controlled randomized clinical trial is to test the effect of 12 weeks of orally administered MitoQ (mitoquinol mesylate) supplementation on cognition in 50 people with early phase…
- Conditions
- Schizophrenia and Related Disorders, Mitochondrial Alteration, Cognitive Impairment
- Trial name
- NCT06191965
- Testing
- MitoQ
- Where
- 3 sites in United States, Switzerland
- Volunteers
- 100 people
- Sponsor
- Mclean Hospital
Neurologic Disorders, Schizophrenia
Characterization of High-Level Cognitive Impairments in Patients With Neuropsychiatric Disorders
Neuropsychiatric disorders are extremely common, severe, and disabling conditions. In the field of psychiatry, they notably include schizophrenia, mood disorders (depressive and bipolar disorders), autism spectrum or…
- Conditions
- Neurologic Disorders, Schizophrenia, Bipolar Disorder (BD), Depressive Disorder
- Trial name
- COGPSY (NCT07295652)
- Testing
- Cognitive assessment, Brain MRI (optional), Electroencephalography (optional)
- Where
- 3 sites in France
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.